These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Hypoglycemic effect of the rhizomes of Polygala senega in normal and diabetic mice and its main component, the triterpenoid glycoside senegin-II. Kako M; Miura T; Nishiyama Y; Ichimaru M; Moriyasu M; Kato A Planta Med; 1996 Oct; 62(5):440-3. PubMed ID: 8923811 [TBL] [Abstract][Full Text] [Related]
44. Pharmacologic treatment of type 2 diabetes mellitus: realities and perspectives. Abdallah MP; Hirbli K J Med Liban; 1999; 47(4):233-7. PubMed ID: 10641451 [No Abstract] [Full Text] [Related]
45. [Glucides in the nutrition of diabetics]. Maillard C Servir; 2002; 50(5):244-6. PubMed ID: 12494529 [No Abstract] [Full Text] [Related]
46. An analysis of the SEVEN system: have we reached the summit of needle-type sensor accuracy? Wentholt IM; DeVries JH J Diabetes Sci Technol; 2009 Sep; 3(5):1155-7. PubMed ID: 20144430 [TBL] [Abstract][Full Text] [Related]
48. Severe iatrogenic hypoglycemia in type 2 diabetes mellitus. Cryer PE Nat Clin Pract Endocrinol Metab; 2007 Jan; 3(1):4-5. PubMed ID: 17179922 [No Abstract] [Full Text] [Related]
49. Defining the role of incretin mimetic therapy in the management of type 2 diabetes. Unger J; Nadeau DA J Fam Pract; 2007 Dec; 56(12 Suppl New):S4-S10. PubMed ID: 18664341 [TBL] [Abstract][Full Text] [Related]
50. Tenacious D. why beta cells are no match for the relentless persistence of type 2 diabetes. Curry A Diabetes Forecast; 2015; 68(5):38-41. PubMed ID: 26491753 [No Abstract] [Full Text] [Related]
51. State of safety. Tsai A Diabetes Forecast; 2015; 68(4):60-2, 65. PubMed ID: 26373221 [No Abstract] [Full Text] [Related]
52. Intensified glucose lowering in type 2 diabetes: don't throw the baby out with the bathwater. DeVries JH Diabetologia; 2011 Mar; 54(3):705-6; author reply 707-8. PubMed ID: 21127831 [No Abstract] [Full Text] [Related]
53. Type of diabetes mellitus: Does it matter to the clinician? Hoogwerf BJ Cleve Clin J Med; 2020 Feb; 87(2):100-108. PubMed ID: 32015063 [TBL] [Abstract][Full Text] [Related]
54. Early and intensive treatment: Glycaemic control in type 2 diabetes. Bailey CJ Diab Vasc Dis Res; 2006 Dec; 3(3):145-6. PubMed ID: 17160908 [No Abstract] [Full Text] [Related]
55. Diabetes: Time for reconciliation between cardiologists and diabetologists. Scheen AJ Nat Rev Cardiol; 2016 Sep; 13(9):509-10. PubMed ID: 27411401 [No Abstract] [Full Text] [Related]
56. Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Litwinoff E; Hurtado Del Pozo C; Ramasamy R; Schmidt AM Clin Pharmacol Ther; 2015 Aug; 98(2):135-44. PubMed ID: 25974754 [TBL] [Abstract][Full Text] [Related]
57. Approaches to treatment 1: How is type 2 diabetes actually treated? Bloomgarden ZT J Diabetes; 2015 Nov; 7(6):747-8. PubMed ID: 26211568 [No Abstract] [Full Text] [Related]
58. Glucose-targeted therapy for subjects with type 2 diabetes mellitus: primum non nocere. Maggi D; Bordone C; Briatore L; Cheli V; Fontana L; Mazzucchelli C; Montecucco F; Adami G; Cordera R Eur J Clin Invest; 2017 Oct; 47(10):691-693. PubMed ID: 28746976 [No Abstract] [Full Text] [Related]
59. Glycemic variability: adverse clinical outcomes and how to improve it? Zhou Z; Sun B; Huang S; Zhu C; Bian M Cardiovasc Diabetol; 2020 Jul; 19(1):102. PubMed ID: 32622354 [TBL] [Abstract][Full Text] [Related]